GSK expects to launch its respiratory syncytial virus (RSV) vaccine in the U.S. this year without supply constraints and sees China as a major future market for the shot, a senior executive told Reuters.
The FBI has assessed that a leak from a laboratory in the central Chinese city of Wuhan likely caused the COVID pandemic, director Christopher Wray said on Tuesday, a claim China said had “no credibility whatsoever”.
As COVID ripped across China and filled emergency wards, privileged patients cut hospital queues because they knew someone, offered a bribe or paid people with connections, said three people who accessed care through such means and seven doctors in six cities.
CanSino Biologics CEO Yu Xuefeng said on Friday he was confident his company’s experimental COVID-19 vaccine using messenger RNA (mRNA) technology was as good as shots from Moderna and Pfizer-BioNTech.
Takeda entered into an exclusive licensing agreement with Hutchmed Limited to develop its colorectal cancer candidate, fruquintinib, beyond mainland China, Hong Kong and Macau.
Sinopharm, now the China distributor of Merck & Co’s COVID-19 antiviral treatment molnupiravir, said its biotech unit received clinical trial approval from the National Medical Products Administration.
Moderna chief executive Stephane Bancel said on Wednesday the U.S. company was in active discussions to supply COVID-19 vaccines to China but gave no further details.
Chinese authorities have acknowledged that supplies of Paxlovid are still insufficient to meet demand, even as Pfizer CEO Albert Bourla said last week that thousands of courses of the treatment were shipped to the country last year and in the past couple of weeks millions more were shipped.
The cooperative agreement involves the distribution of the COVID-19 antibody drug Evusheld.
The company said today it would take legal action against some pharmaceutical companies after noticing that some manufacturers were supplying COVID-19 drugs to some provinces and cities saying the medicines were authorized by Merck.